Skip to main content
main-content

13-09-2022 | ESMO 2022 | Conference coverage | Video

Latest EV-103 update further supports enfortumab vedotin for untreated advanced UC

share
SHARE

Jonathan Rosenberg presents data from a randomized noncomparative cohort of the EV-103 trial of enfortumab vedotin, investigating the agent alone or together with pembrolizumab as a first-line option for cisplatin-ineligible patients with advanced urothelial carcinoma (3:20).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.